NRX Pharmaceuticals Receives Critical FDA Clearance for Ketamine Product
Published on 09/28/2025 at 17:27 | Redaktion boerse-global.de
NRX Pharmaceuticals shares are positioned for a potentially transformative period following a pivotal regulatory development. The U.S. Food and Drug Administration has granted approval for a Suitability Petition concerning KETAFREE
, the company’s preservative-free ketamine formulation. This regulatory milestone enables the immediate resubmission of an Abbreviated New Drug Application, creating a direct pathway toward commercial availability.
This FDA authorization represents a fundamental shift for NRX Pharmaceuticals’ commercial strategy. The clearance facilitates the transition from multi-dose packaging containing preservatives to single-dose, preservative-free presentations. Company leadership emphasizes the dual significance of this advancement: supporting domestic pharmaceutical manufacturing initiatives while eliminating potentially harmful additives... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
